NCT03018288 2025-08-08
Radiation Therapy Plus Temozolomide and Pembrolizumab With and Without HSPPC-96 in Newly Diagnosed Glioblastoma (GBM)
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
Clinical Trials
12 trialsNCT02722512 2025-02-18
Trial of Heat Shock Protein Peptide Complex-96 (HSPPC-96) Vaccine
Ann & Robert H Lurie Children's Hospital of Chicago
Phase 1 Terminated
NCT01814813 2025-01-24
Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery
Alliance for Clinical Trials in Oncology
Phase 2 Terminated
NCT01147536 2021-06-03
Study of Vitespen (HSPPC-96, Oncophage ®) for Immune Response Assessment in Participants With Resectable Renal Cell Carcinoma at Intermediate Risk of Recurrence
Agenus Inc.
Phase 2 Terminated
NCT00293423 2021-05-13
GP96 Heat Shock Protein-Peptide Complex Vaccine in Treating Patients With Recurrent or Progressive Glioma
University of California, San Francisco
Phase 1/2 Completed
NCT00905060 2021-03-24
HeatShock
University of California, San Francisco
Phase 2 Completed
NCT02452281 2016-01-25
Pilot Study to Evaluate the Effects of a Vaccine (HSPPC-96) Combined With Ipilimumab in Patients With Advanced Melanoma
The University of Texas Health Science Center, Houston
Phase 1/2 Withdrawn
NCT00003025 2013-07-03
Vaccine Therapy in Treating Patients With Stage I or Stage II Pancreatic Cancer
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT00005628 2013-06-19
Vaccine Therapy in Treating Patients With Recurrent Soft Tissue Sarcoma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00039000 2012-09-07
Study of Heat Shock Protein-Peptide Complex (HSPPC-96) Versus IL-2/DTIC for Stage IV Melanoma
Agenus Inc.
Phase 3 Completed
NCT00126178 2012-09-07
Clinical Trial Studying a Personalized Cancer Vaccine in Patients With Non-metastatic Kidney Cancer
Agenus Inc.
Phase 3 Terminated
NCT00098085 2009-03-09
Study of the Feasibility to Derive Vaccine From Tumor Tissue in Patients With Non-Small Cell Lung Cancer
Agenus Inc.
Phase 2 Completed